Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 31

References for PMC Articles for PubMed (Select 22545079)

1.

Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings.

Rawizza HE, Chaplin B, Meloni ST, Eisen G, Rao T, Sankalé JL, Dieng-Sarr A, Agbaji O, Onwujekwe DI, Gashau W, Nkado R, Ekong E, Okonkwo P, Murphy RL, Kanki PJ; APIN PEPFAR Team.

Clin Infect Dis. 2011 Dec;53(12):1283-90. doi: 10.1093/cid/cir729.

2.

CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study.

Kahn JG, Marseille E, Moore D, Bunnell R, Were W, Degerman R, Tappero JW, Ekwaru P, Kaharuza F, Mermin J.

BMJ. 2011 Nov 9;343:d6884. doi: 10.1136/bmj.d6884.

3.

Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial.

Mermin J, Ekwaru JP, Were W, Degerman R, Bunnell R, Kaharuza F, Downing R, Coutinho A, Solberg P, Alexander LN, Tappero J, Campbell J, Moore DM.

BMJ. 2011 Nov 9;343:d6792. doi: 10.1136/bmj.d6792.

4.

Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study.

Jani IV, Sitoe NE, Alfai ER, Chongo PL, Quevedo JI, Rocha BM, Lehe JD, Peter TF.

Lancet. 2011 Oct 29;378(9802):1572-9. doi: 10.1016/S0140-6736(11)61052-0. Epub 2011 Sep 25.

PMID:
21951656
5.

Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial.

Laurent C, Kouanfack C, Laborde-Balen G, Aghokeng AF, Mbougua JB, Boyer S, Carrieri MP, Mben JM, Dontsop M, Kazé S, Molinari N, Bourgeois A, Mpoudi-Ngolé E, Spire B, Koulla-Shiro S, Delaporte E; Stratall ANRS 12110/ESTHER study group.

Lancet Infect Dis. 2011 Nov;11(11):825-33. doi: 10.1016/S1473-3099(11)70168-2. Epub 2011 Aug 8.

PMID:
21831714
6.

The DART trial: 'The doctor's dilemma' revisited.

Nunes EP, Grinsztejn B, Schechter M.

J Antimicrob Chemother. 2011 May;66(5):964-7. doi: 10.1093/jac/dkr020. Epub 2011 Feb 15.

7.

Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings.

Phillips AN, Pillay D, Garnett G, Bennett D, Vitoria M, Cambiano V, Lundgren J.

AIDS. 2011 Mar 27;25(6):843-50. doi: 10.1097/QAD.0b013e328344037a.

PMID:
21192233
8.

Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature.

Walensky RP, Ciaranello AL, Park JE, Freedberg KA.

Clin Infect Dis. 2010 Jul 1;51(1):85-92. doi: 10.1086/653119. Review.

9.

Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness.

Kimmel AD, Weinstein MC, Anglaret X, Goldie SJ, Losina E, Yazdanpanah Y, Messou E, Cotich KL, Walensky RP, Freedberg KA; CEPAC-International Investigators.

J Acquir Immune Defic Syndr. 2010 Jul;54(3):258-68. doi: 10.1097/QAI.0b013e3181d0db97.

10.

Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.

Walker AS, Ford D, Gilks CF, Munderi P, Ssali F, Reid A, Katabira E, Grosskurth H, Mugyenyi P, Hakim J, Darbyshire JH, Gibb DM, Babiker AG.

Lancet. 2010 Apr 10;375(9722):1278-86. doi: 10.1016/S0140-6736(10)60057-8. Epub 2010 Mar 27.

11.

A cluster randomized trial of routine HIV-1 viral load monitoring in Zambia: study design, implementation, and baseline cohort characteristics.

Koethe JR, Westfall AO, Luhanga DK, Clark GM, Goldman JD, Mulenga PL, Cantrell RA, Chi BH, Zulu I, Saag MS, Stringer JS.

PLoS One. 2010 Mar 12;5(3):e9680. doi: 10.1371/journal.pone.0009680. Erratum in: PLoS One. 2010; 5(3) doi: 10.1371/annotation/dbc3ee9b-dab4-494b-87d1-7c32b8d684b5.

12.

Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.

DART Trial Team, Mugyenyi P, Walker AS, Hakim J, Munderi P, Gibb DM, Kityo C, Reid A, Grosskurth H, Darbyshire JH, Ssali F, Bray D, Katabira E, Babiker AG, Gilks CF, Grosskurth H, Munderi P, Kabuye G, Nsibambi D, Kasirye R, Zalwango E, Nakazibwe M, Kikaire B, Nassuna G, Massa R, Fadhiru K, Namyalo M, Zalwango A, Generous L, Khauka P, Rutikarayo N, Nakahima W, Mugisha A, Todd J, Levin J, Muyingo S, Ruberantwari A, Kaleebu P, Yirrell D, Ndembi N, Lyagoba F, Hughes P, Aber M, Lara AM, Foster S, Amurwon J, Wakholi BN, Whitworth J, Wangati K, Amuron B, Kajungu D, Nakiyingi J, Omony W, Fadhiru K, Nsibambi D, Khauka P, Mugyenyi P, Kityo C, Ssali F, Tumukunde D, Otim T, Kabanda J, Musana H, Akao J, Kyomugisha H, Byamukama A, Sabiiti J, Komugyena J, Wavamunno P, Mukiibi S, Drasiku A, Byaruhanga R, Labeja O, Katundu P, Tugume S, Awio P, Namazzi A, Bakeinyaga GT, Katabira H, Abaine D, Tukamushaba J, Anywar W, Ojiambo W, Angweng E, Murungi S, Haguma W, Atwiine S, Kigozi J, Namale L, Mukose A, Mulindwa G, Atwiine D, Muhwezi A, Nimwesiga E, Barungi G, Takubwa J, Murungi S, Mwebesa D, Kagina G, Mulindwa M, Ahimbisibwe F, Mwesigwa P, Akuma S, Zawedde C, Nyiraguhirwa D, Tumusiime C, Bagaya L, Namara W, Kigozi J, Karungi J, Kankunda R, Enzama R, Latif A, Hakim J, Robertson V, Reid A, Chidziva E, Bulaya-Tembo R, Musoro G, Taziwa F, Chimbetete C, Chakonza L, Mawora A, Muvirimi C, Tinago G, Svovanapasis P, Simango M, Chirema O, Machingura J, Mutsai S, Phiri M, Bafana T, Chirara M, Muchabaiwa L, Muzambi M, Mutowo J, Chivhunga T, Chigwedere E, Pascoe M, Warambwa C, Zengeza E, Mapinge F, Makota S, Jamu A, Ngorima N, Chirairo H, Chitsungo S, Chimanzi J, Maweni C, Warara R, Matongo M, Mudzingwa S, Jangano M, Moyo K, Vere L, Mdege N, Machingura I, Katabira E, Ronald A, Kambungu A, Lutwama F, Mambule I, Nanfuka A, Walusimbi J, Nabankema E, Nalumenya R, Namuli T, Kulume R, Namata I, Nyachwo L, Florence A, Kusiima A, Lubwama E, Nairuba R, Oketta F, Buluma E, Waita R, Ojiambo H, Sadik F, Wanyama J, Nabongo P, Oyugi J, Sematala F, Muganzi A, Twijukye C, Byakwaga H, Ochai R, Muhweezi D, Coutinho A, Etukoit B, Gilks C, Boocock K, Puddephatt C, Grundy C, Bohannon J, Winogron D, Gibb DM, Burke A, Bray D, Babiker A, Walker AS, Wilkes H, Rauchenberger M, Sheehan S, Spencer-Drake C, Taylor K, Spyer M, Ferrier A, Naidoo B, Dunn D, Goodall R, Darbyshire JH, Peto L, Nanfuka R, Mufuka-Kapuya C, Kaleebu P, Pillay D, Robertson V, Yirrell D, Tugume S, Chirara M, Katundu P, Ndembi N, Lyagoba F, Dunn D, Goodall R, McCormick A, Lara AM, Foster S, Amurwon J, Wakholi BN, Kigozi J, Muchabaiwa L, Muzambi M, Weller I, Babiker A, Bahendeka S, Bassett M, Wapakhabulo AC, Darbyshire JH, Gazzard B, Gilks C, Grosskurth H, Hakim J, Latif A, Mapuchere C, Mugurungi O, Mugyenyi P, Burke C, Jones S, Newland C, Pearce G, Rahim S, Rooney J, Smith M, Snowden W, Steens JM, Breckenridge A, McLaren A, Hill C, Matenga J, Pozniak A, Serwadda D, Peto T, Palfreeman A, Borok M, Katabira E.

Lancet. 2010 Jan 9;375(9709):123-31. doi: 10.1016/S0140-6736(09)62067-5. Epub 2009 Dec 8.

13.

Cost-effectiveness of strategies for monitoring the response to antiretroviral therapy in resource-limited settings.

Phillips AN, Gilks C, Lundgren JD.

Arch Intern Med. 2009 May 11;169(9):904; author reply 904-5. doi: 10.1001/archinternmed.2009.88. No abstract available.

PMID:
19433706
14.

Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis.

Bendavid E, Young SD, Katzenstein DA, Bayoumi AM, Sanders GD, Owens DK.

Arch Intern Med. 2008 Sep 22;168(17):1910-8. doi: 10.1001/archinternmed.2008.1.

15.

The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa.

Rosen S, Long L, Sanne I.

Trop Med Int Health. 2008 Aug;13(8):1005-15. doi: 10.1111/j.1365-3156.2008.02114.x. Epub 2008 Jul 8.

16.

Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model.

Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD.

Lancet. 2008 Apr 26;371(9622):1443-51. doi: 10.1016/S0140-6736(08)60624-8.

PMID:
18440426
18.

The cost effectiveness of antiretroviral treatment strategies in resource-limited settings.

Bishai D, Colchero A, Durack DT.

AIDS. 2007 Jun 19;21(10):1333-40.

PMID:
17545710
19.

Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda.

Weidle PJ, Wamai N, Solberg P, Liechty C, Sendagala S, Were W, Mermin J, Buchacz K, Behumbiize P, Ransom RL, Bunnell R.

Lancet. 2006 Nov 4;368(9547):1587-94.

PMID:
17084759
20.

Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings.

Moore DM, Mermin J, Awor A, Yip B, Hogg RS, Montaner JS.

J Acquir Immune Defic Syndr. 2006 Dec 1;43(4):436-9.

PMID:
17019367
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk